Posted by Michael Wonder on 30 Sep 2019
Schedule of Pharmaceutical Benefits - 1 October 2019 update
1 October 2019 - The October 2019 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The October issue of the Schedule includes several new listings:
- Atezolizumab (Tecentriq) - new indication
- Bevacizumab (Avastin) - new indication
- Blinatumomab (Blincyto) - restriction change
- Clostridium botulinum toxin type A (Dysport) - new indication
- Inotuzumab ozogamicin (Besponsa) - restriction change
- Insulin glargine (Semglee) - new biosimilar medicine
- Ocriplasmin (Jetrea RTU) - new formulation
- Rituximab (Riximyo) - new biosimilar medicine
- Teduglutide (Revestive) - new medicine
